ABBOTT SHOULD REPEAT STUDY OF ULTANE LOW-FLOW USE RISK CONDUCTED BY OHMEDA CONSULTANT; WARNING SHOULD REMAIN IN LABELING, FDA COMMITTEE RECOMMENDS
Executive Summary
A warning in the labeling of Abbott's anesthetic Ultane should remain in labeling pending review of results from two small studies of Ultane-associated risk in low-flow systems conducted by an Ohmeda consultant, FDA's Anesthetic and Life Support Drugs Advisory Committee determined April 30.